急性心筋梗塞の世界市場レポート 2025年

急性心筋梗塞市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.0％で19億7,000万米ドルに成長します。予測期間に予測される成長は、低侵襲心臓処置に対する需要の高まり、心臓修復のための再生医療への投資の増加、肥満と糖尿病の有病率の上昇、心臓病に対する個別化医療への注目の拡大に起因しています。この期間の主な動向には、AIを活用した早期発見システム、ウェアラブルECGモニタリング機器、ナノテクノロジーを活用したドラッグデリバリー、心臓組織の3Dバイオプリンティング、高度なロボット支援心臓手術などがあります。

高血圧の有病率の上昇は、急性心筋梗塞（AMI）市場の成長を大きく牽引すると予想されます。持続的な高血圧を特徴とする高血圧症は、心臓病、脳卒中、その他の心血管合併症の主要な危険因子です。高血圧症例の増加は、デスクワークによる座りがちな行動、過度のスクリーン使用時間、最小限の身体活動といった現代のライフスタイル要因に起因しています。高血圧は動脈を傷つけ、プラークの蓄積を促進し、血栓のリスクを高める。例えば、オーストラリア統計局の報告によると、オーストラリアにおける高血圧の有病率は、2022年に11.6％（約300万人）に達しました。高血圧率の上昇に伴い、急性心筋梗塞市場の成長もそれに追随すると予想されます。

急性心筋梗塞市場の主要プレーヤーは、製品ラインナップを充実させ治療成績を向上させるため、規制当局の承認取得にますます注力するようになっています。FDAやEMAなどの規制当局による承認は、医薬品や医療機器が必要な安全性、有効性、品質基準を満たすために不可欠です。例えば、2025年3月、中国のバイオ医薬品会社であるSungen Biomedicalは、モノクローナル抗体医薬品SGC001のFDA Fast Track Designationを取得しました。この医薬品は、急性心筋梗塞の緊急治療薬としては初めてのもので、心筋細胞のアポトーシスを抑制し、虚血部位の血流を改善するという有望な前臨床試験結果を示しています。ファスト・トラックの認定により、Sungen Biomedical社は承認プロセスを迅速に進めることが可能となり、AMI患者にとって救命の可能性のあるこの治療薬への迅速なアクセスが可能となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界急性心筋梗塞PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の急性心筋梗塞市場：成長率分析
• 世界の急性心筋梗塞市場の実績：規模と成長, 2019-2024
• 世界の急性心筋梗塞市場の予測：規模と成長, 2024-2029, 2034F
• 世界急性心筋梗塞総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の急性心筋梗塞市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ST上昇型心筋梗塞（STEMI）
• 非ST上昇型心筋梗塞（NSTEMI）
• 世界の急性心筋梗塞市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血栓溶解療法
• 経皮的冠動脈インターベンション（PCI）
• 冠動脈バイパス移植術（CABG）
• 医薬品
• 世界の急性心筋梗塞市場診断方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 心電図
• 心臓バイオマーカー
• 心エコー検査
• 冠動脈造影検査
• 磁気共鳴画像法（MRI）
• コンピュータ断層撮影（CT）スキャン
• 世界の急性心筋梗塞市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口経路
• 静脈内（IV）経路
• 皮下経路
• 経皮経路
• 舌下経路
• 世界の急性心筋梗塞市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 外来手術センター
• 専門心臓センター
• 調査機関
• 世界の急性心筋梗塞市場ST上昇型心筋梗塞（STEMI）の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 前部ST上昇型心筋梗塞（STEMI）
• 下壁ST上昇型心筋梗塞（STEMI）
• 後壁ST上昇型心筋梗塞（STEMI）
• 側方ST上昇型心筋梗塞（STEMI）
• 右室ST上昇型心筋梗塞（STEMI）
• 広範囲（大規模）ST上昇型心筋梗塞（STEMI）
• 世界の急性心筋梗塞市場非ST上昇型心筋梗塞（NSTEMI）の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 心内膜下非ST上昇型心筋梗塞（NSTEMI）
• 部分層非ST上昇型心筋梗塞（NSTEMI）
• 多枝非ST上昇型心筋梗塞（NSTEMI）
• 無症候性非ST上昇型心筋梗塞（NSTEMI）
• 再発性非ST上昇型心筋梗塞（NSTEMI）

第7章 地域別・国別分析

• 世界の急性心筋梗塞市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の急性心筋梗塞市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 急性心筋梗塞市場：競合情勢
• 急性心筋梗塞市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca plc
• Abbott Laboratories
• Novartis AG
• GSK plc
• Eli Lilly and Company
• Siemens Healthineers
• Fujifilm Holdings Corporation
• Koninklijke Philips N.V.
• Boston Scientific Corporation
• Daiichi Sankyo Company Limited
• Terumo Corporation
• MicroPort Scientific Corporation
• Ionis Pharmaceuticals Inc.
• CellProthera

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 急性心筋梗塞市場2029：新たな機会を提供する国
• 急性心筋梗塞市場2029：新たな機会を提供するセグメント
• 急性心筋梗塞市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Acute myocardial infarction (MI), commonly known as a heart attack, occurs when there is a sudden reduction or complete cessation of blood flow to one or more coronary arteries, resulting in the death of heart muscle tissue. This is typically caused by the rupture of atherosclerotic plaques, leading to a blockage in the blood flow.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of myocardial infarction are ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). STEMI is a more severe form of heart attack, characterized by a complete blockage of a coronary artery, significantly reducing blood flow to the heart muscle. Treatment for acute myocardial infarction involves thrombolytic therapy, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and medications. Diagnosis is performed using various methods, including electrocardiograms (ECG), cardiac biomarkers, echocardiography, coronary angiography, MRI, and CT scans. Medications are administered through different routes, including oral, intravenous (IV), subcutaneous, transdermal, and sublingual. The primary end users for these treatments include hospitals, clinics, ambulatory surgical centers, specialty cardiac centers, and research institutes.

The acute myocardial infarction market research report is one of a series of new reports from The Business Research Company that provides acute myocardial infarction market statistics, including acute myocardial infarction industry global market size, regional shares, competitors with an acute myocardial infarction market share, detailed acute myocardial infarction market segments, market trends and opportunities, and any further data you may need to thrive in the acute myocardial infarction industry. This acute myocardial infarction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute myocardial infarction market size has grown strongly in recent years. It will grow from$1.47 billion in 2024 to $1.56 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth observed during the historical period can be linked to a rise in heart diseases associated with smoking, a higher prevalence of hypertension, advancements in emergency medical services, increased awareness of heart disease risk factors, and the early use of aspirin in cardiovascular treatment.

The acute myocardial infarction market size is expected to see strong growth in the next few years. It will grow to$1.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth projected for the forecast period can be attributed to the growing demand for minimally invasive cardiac procedures, increased investment in regenerative medicine for heart repair, the rising prevalence of obesity and diabetes, and an expanding focus on personalized medicine for heart disease. Key trends during this period include AI-driven early detection systems, wearable ECG monitoring devices, nanotechnology-based drug delivery, 3D bioprinting of cardiac tissues, and advanced robotic-assisted cardiac surgeries.

The rising prevalence of hypertension is expected to significantly drive the growth of the acute myocardial infarction (AMI) market. Hypertension, characterized by persistently high blood pressure, is a major risk factor for heart disease, stroke, and other cardiovascular complications. The increase in hypertension cases can be attributed to modern lifestyle factors, such as sedentary behavior from desk jobs, excessive screen time, and minimal physical activity. Hypertension damages the arteries, promotes plaque buildup, and increases the risk of blood clots, all of which can contribute to acute myocardial infarction. For example, according to a report by the Australian Bureau of Statistics, the prevalence of hypertension in Australia reached 11.6% (approximately 3.0 million people) in 2022. As hypertension rates rise, the growth of the acute myocardial infarction market is anticipated to follow suit.

Key players in the acute myocardial infarction market are increasingly focusing on obtaining regulatory approvals to enhance their product offerings and improve treatment outcomes. Regulatory approvals from agencies such as the FDA and EMA are vital in ensuring that drugs and medical devices meet required safety, efficacy, and quality standards. For instance, in March 2025, Sungen Biomedical, a China-based biopharmaceutical company, received FDA Fast Track Designation for its monoclonal antibody drug, SGC001. This drug, the first of its kind for the emergency treatment of acute myocardial infarction, has shown promising preclinical results in reducing cardiomyocyte apoptosis and improving blood flow in ischemic areas. The Fast Track status allows Sungen Biomedical to fast-track the approval process, enabling quicker access to this potentially life-saving therapy for AMI patients.

In February 2023, BioCardia Inc., a U.S.-based biotechnology company, extended its partnership with CellProthera to advance the development of ProtheraCytes for treating acute myocardial infarction. BioCardia plans to leverage its Helix transendocardial biotherapeutic delivery system for CellProthera's Phase I/IIb EXCELLENT study, focused on its lead product candidate, ProtheraCytes. CellProthera, a France-based company, specializes in regenerative therapies for AMI, and this partnership aims to develop innovative treatments that could significantly improve heart attack recovery outcomes.

Major players in the acute myocardial infarction market are Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Siemens Healthineers, Fujifilm Holdings Corporation, Koninklijke Philips N.V., Boston Scientific Corporation, Daiichi Sankyo Company Limited, Terumo Corporation, MicroPort Scientific Corporation, Ionis Pharmaceuticals Inc., CellProthera, Athersys Inc., BioCardia Inc., and Serca Pharmaceuticals.

North America was the largest region in the acute myocardial infarction market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute myocardial infarction report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute myocardial infarction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute myocardial infarction market consists of revenues earned by entities by providing services such as diagnostic testing, telemedicine consultations, remote patient monitoring, pharmaceutical treatments, and post-acute myocardial infarction (AMI) management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute myocardial infarction market also includes sales of pharmaceutical drugs, medical devices, diagnostic tools, wearable cardiac monitors, and telemedicine platforms for remote cardiac care. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Myocardial Infarction Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute myocardial infarction market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute myocardial infarction ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute myocardial infarction market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: ST-Elevation Myocardial Infarction (STEMI); Non-ST-Elevation Myocardial Infarction (NSTEMI)
• 2) By Treatment Type: Thrombolytic Therapy; Percutaneous Coronary Intervention (PCI); Coronary Artery Bypass Grafting (CABG); Medications
• 3) By Diagnosis Method: Electrocardiogram; Cardiac Biomarkers; Echocardiography; Coronary Angiography; Magnetic Resonance Imaging (MRI); Computed Tomography (CT) Scan
• 4) By Route Of Administration: Oral Route; Intravenous (IV) Route; Subcutaneous Route; Transdermal Route; Sublingual Route
• 5) By End User: Hospitals And Clinics; Ambulatory Surgical Centers; Specialty Cardiac Centers; Research Institutes
• Subsegments:
• 1) ST-Elevation Myocardial Infarction (STEMI): Anterior ST-Elevation Myocardial Infarction (STEMI); Inferior ST-Elevation Myocardial Infarction (STEMI); Posterior ST-Elevation Myocardial Infarction (STEMI); Lateral ST-Elevation Myocardial Infarction (STEMI); Right Ventricular ST-Elevation Myocardial Infarction (STEMI); Extensive (Large) ST-Elevation Myocardial Infarction (STEMI)
• 2) Non-ST-Elevation Myocardial Infarction (NSTEMI): Subendocardial Non-ST-Elevation Myocardial Infarction (NSTEMI); Partial Thickness Non-ST-Elevation Myocardial Infarction (NSTEMI); Multi-Vessel Non-ST-Elevation Myocardial Infarction (NSTEMI); Silent Non-ST-Elevation Myocardial Infarction (NSTEMI); Recurrent Non-ST-Elevation Myocardial Infarction (NSTEMI)
• Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Myocardial Infarction Market Characteristics

3. Acute Myocardial Infarction Market Trends And Strategies

4. Acute Myocardial Infarction Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Acute Myocardial Infarction Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Myocardial Infarction PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Myocardial Infarction Market Growth Rate Analysis
• 5.4. Global Acute Myocardial Infarction Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Myocardial Infarction Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Myocardial Infarction Total Addressable Market (TAM)

6. Acute Myocardial Infarction Market Segmentation

• 6.1. Global Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• ST-Elevation Myocardial Infarction (STEMI)
• Non-ST-Elevation Myocardial Infarction (NSTEMI)
• 6.2. Global Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thrombolytic Therapy
• Percutaneous Coronary Intervention (PCI)
• Coronary Artery Bypass Grafting (CABG)
• Medications
• 6.3. Global Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Electrocardiogram
• Cardiac Biomarkers
• Echocardiography
• Coronary Angiography
• Magnetic Resonance Imaging (MRI)
• Computed Tomography (CT) Scan
• 6.4. Global Acute Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Route
• Intravenous (IV) Route
• Subcutaneous Route
• Transdermal Route
• Sublingual Route
• 6.5. Global Acute Myocardial Infarction Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Ambulatory Surgical Centers
• Specialty Cardiac Centers
• Research Institutes
• 6.6. Global Acute Myocardial Infarction Market, Sub-Segmentation Of ST-Elevation Myocardial Infarction (STEMI), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anterior ST-Elevation Myocardial Infarction (STEMI)
• Inferior ST-Elevation Myocardial Infarction (STEMI)
• Posterior ST-Elevation Myocardial Infarction (STEMI)
• Lateral ST-Elevation Myocardial Infarction (STEMI)
• Right Ventricular ST-Elevation Myocardial Infarction (STEMI)
• Extensive (Large) ST-Elevation Myocardial Infarction (STEMI)
• 6.7. Global Acute Myocardial Infarction Market, Sub-Segmentation Of Non-ST-Elevation Myocardial Infarction (NSTEMI), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subendocardial Non-ST-Elevation Myocardial Infarction (NSTEMI)
• Partial Thickness Non-ST-Elevation Myocardial Infarction (NSTEMI)
• Multi-Vessel Non-ST-Elevation Myocardial Infarction (NSTEMI)
• Silent Non-ST-Elevation Myocardial Infarction (NSTEMI)
• Recurrent Non-ST-Elevation Myocardial Infarction (NSTEMI)

7. Acute Myocardial Infarction Market Regional And Country Analysis

• 7.1. Global Acute Myocardial Infarction Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Myocardial Infarction Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Myocardial Infarction Market

• 8.1. Asia-Pacific Acute Myocardial Infarction Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Myocardial Infarction Market

• 9.1. China Acute Myocardial Infarction Market Overview
• 9.2. China Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Myocardial Infarction Market

• 10.1. India Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Myocardial Infarction Market

• 11.1. Japan Acute Myocardial Infarction Market Overview
• 11.2. Japan Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Myocardial Infarction Market

• 12.1. Australia Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Myocardial Infarction Market

• 13.1. Indonesia Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Myocardial Infarction Market

• 14.1. South Korea Acute Myocardial Infarction Market Overview
• 14.2. South Korea Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Myocardial Infarction Market

• 15.1. Western Europe Acute Myocardial Infarction Market Overview
• 15.2. Western Europe Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Myocardial Infarction Market

• 16.1. UK Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Myocardial Infarction Market

• 17.1. Germany Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Myocardial Infarction Market

• 18.1. France Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Myocardial Infarction Market

• 19.1. Italy Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Myocardial Infarction Market

• 20.1. Spain Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Myocardial Infarction Market

• 21.1. Eastern Europe Acute Myocardial Infarction Market Overview
• 21.2. Eastern Europe Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Myocardial Infarction Market

• 22.1. Russia Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Myocardial Infarction Market

• 23.1. North America Acute Myocardial Infarction Market Overview
• 23.2. North America Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Myocardial Infarction Market

• 24.1. USA Acute Myocardial Infarction Market Overview
• 24.2. USA Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Myocardial Infarction Market

• 25.1. Canada Acute Myocardial Infarction Market Overview
• 25.2. Canada Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Myocardial Infarction Market

• 26.1. South America Acute Myocardial Infarction Market Overview
• 26.2. South America Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Myocardial Infarction Market

• 27.1. Brazil Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Myocardial Infarction Market

• 28.1. Middle East Acute Myocardial Infarction Market Overview
• 28.2. Middle East Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Myocardial Infarction Market

• 29.1. Africa Acute Myocardial Infarction Market Overview
• 29.2. Africa Acute Myocardial Infarction Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Myocardial Infarction Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Myocardial Infarction Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Myocardial Infarction Market Competitive Landscape And Company Profiles

• 30.1. Acute Myocardial Infarction Market Competitive Landscape
• 30.2. Acute Myocardial Infarction Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Acute Myocardial Infarction Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca plc
• 31.3. Abbott Laboratories
• 31.4. Novartis AG
• 31.5. GSK plc
• 31.6. Eli Lilly and Company
• 31.7. Siemens Healthineers
• 31.8. Fujifilm Holdings Corporation
• 31.9. Koninklijke Philips N.V.
• 31.10. Boston Scientific Corporation
• 31.11. Daiichi Sankyo Company Limited
• 31.12. Terumo Corporation
• 31.13. MicroPort Scientific Corporation
• 31.14. Ionis Pharmaceuticals Inc.
• 31.15. CellProthera

32. Global Acute Myocardial Infarction Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Myocardial Infarction Market

34. Recent Developments In The Acute Myocardial Infarction Market

35. Acute Myocardial Infarction Market High Potential Countries, Segments and Strategies

• 35.1 Acute Myocardial Infarction Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Myocardial Infarction Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Myocardial Infarction Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34743_Acute_Myocardial_Infarction_GMR_2025